Press release
Medullary Thyroid Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight
Medullary Thyroid Cancer Treatment Market
The Medullary Thyroid Cancer market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Medullary Thyroid Cancer market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Medullary Thyroid Cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Medullary Thyroid Cancer market.
Request for a Free Sample Report @ Medullary Thyroid Cancer Market Forecast - https://www.delveinsight.com/report-store/medullary-thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Some facts of the Medullary Thyroid Cancer Market Report are:
• According to DelveInsight, Medullary Thyroid Cancer market size is expected to grow at a decent CAGR by 2032.
• Leading Medullary Thyroid Cancer companies working in the market are Bristol-Myers Squibb, Takeda, NantCell, Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Bayer, Novartis, Hutchison Medipharma Limited, Turning Point Therapeutics, Inc, and others.
• Key Medullary Thyroid Cancer Therapies expected to launch in the market are Selpercatinib, Cabozantinib (Cometriq), Vandetanib (Caprelsa), Pralsetinib (Gavreto), LOXO-292 (Selpercatinib), Lenvatinib (Lenvima), Sorafenib (Nexavar) and many others.
• In March 2025, Loxo Oncology, Inc. announced results of a Multicenter, Randomized, Open-label, Phase 3 Trial Comparing Selpercatinib to Physicians Choice of Cabozantinib or Vandetanib in Patients With Progressive, Advanced, Kinase Inhibitor Naïve, RET-Mutant Medullary Thyroid Cancer (LIBRETTO-531)
• In March 2025, Eli Lilly and Company announced results of a Phase 2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including Rearranged in Transfection (RET) Fusion-Positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
• In March 2025, Eli Lilly and Company announced results of a Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors
• On September 27, 2024, the FDA approved selpercatinib (Retevmo, Eli Lilly and Company) for adults and children aged 2 and older with advanced or metastatic medullary thyroid cancer (MTC) with an RET mutation, as detected by an FDA-approved test. The approval is based on positive results from the LIBRETTO-531 clinical trial (NCT04211337).
Medullary Thyroid Cancer Overview
Medullary Thyroid Cancer (MTC) is a rare but aggressive type of thyroid cancer that arises from the parafollicular C cells of the thyroid gland, which produce the hormone calcitonin. Medullary Thyroid Cancer accounts for approximately 3-5% of all thyroid cancers and can occur sporadically or as part of hereditary syndromes like Multiple Endocrine Neoplasia type 2 (MEN2). Unlike other thyroid cancers, Medullary Thyroid Cancer does not originate from thyroid follicular cells and is often associated with genetic mutations, particularly in the RET proto-oncogene.
Medullary Thyroid Cancer symptoms may include a palpable neck mass, difficulty swallowing, hoarseness, and diarrhea due to elevated calcitonin levels. Diagnosis of Medullary Thyroid Cancer involves serum calcitonin and carcinoembryonic antigen (CEA) tests, genetic testing for RET mutations, ultrasound, and fine-needle aspiration biopsy.
Medullary Thyroid Cancer treatment primarily consists of surgical thyroidectomy, often combined with lymph node dissection. Targeted therapies, such as RET inhibitors (selpercatinib, pralsetinib), have shown promise in advanced or metastatic cases. Unlike other thyroid cancers, Medullary Thyroid Cancer is less responsive to radioactive iodine therapy. Ongoing research into new treatment options continues to improve outcomes for patients with Medullary Thyroid Cancer.
Do you know what will be the Medullary Thyroid Cancer market share in 7MM by 2032 @ https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Medullary Thyroid Cancer Market
The Medullary Thyroid Cancer market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Medullary Thyroid Cancer market trends by analyzing the impact of current Medullary Thyroid Cancer therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.
This segment gives a thorough detail of the Medullary Thyroid Cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Medullary Thyroid Cancer market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The global medullary thyroid cancer treatment market growth is expected to driven by number of factors such as increased prevalence of thyroid cancers, increasing advancements in treatment of medullary thyroid cancers, good prognosis rates in early detection, increasing demand for preventive care leading to early diagnosis and increasing awareness.
According to DelveInsight, the Medullary Thyroid Cancer market in 7MM is expected to witness a major change in the study period 2019-2032.
Medullary Thyroid Cancer Epidemiology
The Medullary Thyroid Cancer epidemiology section provides insights into the historical and current Medullary Thyroid Cancer patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Medullary Thyroid Cancer market report also provides the diagnosed patient pool, trends, and assumptions.
Interested to know how the emerging diagnostic approaches will be contributing in increased Medullary Thyroid Cancer diagnosed prevalence pool? Download report @ Medullary Thyroid Cancer prevalence - https://www.delveinsight.com/report-store/medullary-thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Medullary Thyroid Cancer Drugs Uptake
This section focuses on the uptake rate of the potential Medullary Thyroid Cancer drugs recently launched in the Medullary Thyroid Cancer market or expected to be launched in 2019-2032. The analysis covers the Medullary Thyroid Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.
Medullary Thyroid Cancer Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Medullary Thyroid Cancer market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Medullary Thyroid Cancer Pipeline Development Activities
The Medullary Thyroid Cancer report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Medullary Thyroid Cancer key players involved in developing targeted therapeutics.
Download report to know which TOP 3 therapies will be capturing the largest Medullary Thyroid Cancer market share by 2032? Click here @ https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Medullary Thyroid Cancer Therapeutics Assessment
Major key companies are working proactively in the Medullary Thyroid Cancer Therapeutics market to develop novel therapies which will drive the Medullary Thyroid Cancer treatment markets in the upcoming years are Bristol-Myers Squibb (NYSE: BMY), Takeda (TSE: 4502), NantCell, Inc. (IBRX), Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Private), CSPC ZhongQi Pharmaceutical Technology Co., Ltd. (HKG: 1093), Bayer (OTCMKTS: BAYRY), Novartis (NYSE: NVS), Hutchison Medipharma Limited (NASDAQ: HCM), and Turning Point Therapeutics, Inc. (NASDAQ: TPTX), among others.
Download sample report @ Medullary Thyroid Cancer Clinical Trials - https://www.delveinsight.com/sample-request/medullary-thyroid-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
Medullary Thyroid Cancer Report Key Insights
1. Medullary Thyroid Cancer Patient Population
2. Medullary Thyroid Cancer Market Size and Trends
3. Key Cross Competition in the Medullary Thyroid Cancer Market
4. Medullary Thyroid Cancer Market Dynamics (Key Drivers and Barriers)
5. Medullary Thyroid Cancer Market Opportunities
6. Medullary Thyroid Cancer Therapeutic Approaches
7. Medullary Thyroid Cancer Pipeline Analysis
8. Medullary Thyroid Cancer Current Treatment Practices/Algorithm
9. Impact of Emerging Therapies on the Medullary Thyroid Cancer Market
Table of Contents
1. Key Insights
2. Executive Summary
3. Medullary Thyroid Cancer Competitive Intelligence Analysis
4. Medullary Thyroid Cancer Market Overview at a Glance
5. Medullary Thyroid Cancer Disease Background and Overview
6. Medullary Thyroid Cancer Patient Journey
7. Medullary Thyroid Cancer Epidemiology and Patient Population
8. Medullary Thyroid Cancer Treatment Algorithm, Current Treatment, and Medical Practices
9. Medullary Thyroid Cancer Unmet Needs
10. Key Endpoints of Medullary Thyroid Cancer Treatment
11. Medullary Thyroid Cancer Marketed Products
12. Medullary Thyroid Cancer Emerging Therapies
13. Medullary Thyroid Cancer Seven Major Market Analysis
14. Attribute Analysis
15. Medullary Thyroid Cancer Market Outlook (7 major markets)
16. Medullary Thyroid Cancer Access and Reimbursement Overview
17. KOL Views on the Medullary Thyroid Cancer Market
18. Medullary Thyroid Cancer Market Drivers
19. Medullary Thyroid Cancer Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
Trending Reports:
• Angina Pectoris Market: https://www.delveinsight.com/report-store/angina-angina-pectoris-market
• Anorectal Malformation Market: https://www.delveinsight.com/report-store/anorectal-malformation-market
• Anovulation Market: https://www.delveinsight.com/report-store/anovulation-market
• Anterior Cruciate Ligament Injuries Market: https://www.delveinsight.com/report-store/anterior-cruciate-ligament-injuries-epidemiology-forecast
• Antibody Mediated Rejection Market: https://www.delveinsight.com/report-store/antibody-mediated-rejection-market
• Antiphospholipid Syndrome Aps Market: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market
• Arthroscopic Shavers Market: https://www.delveinsight.com/report-store/arthroscopic-shavers-market
• Arthroscopy Devices Market: https://www.delveinsight.com/report-store/arthroscopy-devices-market
• Artificial Kidney Market: https://www.delveinsight.com/report-store/artificial-kidney-market
• Aspergillosis Market: https://www.delveinsight.com/report-store/aspergillosis-market
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Atypical Teratoid Rhabdoid Tumors Market: https://www.delveinsight.com/report-store/atypical-teratoid-rhabdoid-tumors-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/axillary-hyperhidrosis-ahh-market
• Bacterial Pyogenic Meningitis Market: https://www.delveinsight.com/report-store/bacterial-pyogenic-meningitis-market
• Becker Muscular Dystrophy Market: https://www.delveinsight.com/report-store/becker-muscular-dystrophy-market
• Bile Duct Neoplasm Market: https://www.delveinsight.com/report-store/bile-duct-cancer-market
• Bipolar Depression Market: https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Bradycardia Treatment Devices Market: https://www.delveinsight.com/report-store/bradycardia-treatment-devices-market
• Bronchopulmonary Dysplasia Market: https://www.delveinsight.com/report-store/bronchopulmonary-dysplasia-market
• Bunion Market: https://www.delveinsight.com/report-store/bunion-market
• Cancer Anorexia Market: https://www.delveinsight.com/report-store/cancer-anorexia-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Cardiotoxicity Market: https://www.delveinsight.com/report-store/cardiotoxicity-market
• Carpal Tunnel Syndrome Market: https://www.delveinsight.com/report-store/carpal-tunnel-release-system-market
• Catheter-related Bloodstream Infections Market: https://www.delveinsight.com/report-store/catheter-related-bloodstream-infection-crbsi-market-size-analysis
Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Medullary Thyroid Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Statistics, Revenue, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight here
News-ID: 3947587 • Views: …
More Releases from DelveInsight Business Research
Pharma Asset Management Success Story: Strategic In-Licensing in the Atrial Fibr …
DelveInsight, a leading business consulting and market research firm, is pleased to announce the successful completion of an Asset Prioritization project that enabled a mid-sized pharmaceutical client to identify, evaluate, and secure a high-value therapeutic asset for in-licensing in the Atrial Fibrillation (AF) space. The case study highlights how evidence-based insights, structured methodologies, and multi-layered evaluations supported the client in achieving its long-term strategic growth goals.
Objective of the Case Study
The…
Myopia Clinical Trials Outlook 2025: Competitive Landscape, Regulatory Milestone …
(Albany, USA) - DelveInsight's newly released report, "Myopia Pipeline Insight 2025," delivers an in-depth assessment of the clinical trial landscape, regulatory progress, and therapeutic development trends shaping the Myopia therapeutics market. The analysis highlights ongoing clinical advancements, pipeline opportunities, and the potential impact of emerging therapies on patient care and market dynamics.
According to DelveInsight's evaluation, the Myopia pipeline remains highly active, with 8+ pharmaceutical and biotechnology companies investigating more than…
Global Biopsy Devices Market to Reach USD 10.81 Billion by 2032, Driven by Risin …
The global biopsy devices market is poised for significant growth, with market size projected to increase from USD 5,813.16 million in 2024 to USD 10,812.77 million by 2032, expanding at a CAGR of 8.09% during 2025-2032. The robust expansion is being driven by the growing incidence of cancers, rising demand for minimally invasive diagnostic procedures, and rapid advancements in biopsy technologies.
Biopsy devices play a crucial role in disease diagnosis by…
Global General Surgery Devices Market to Reach USD 35.4 Billion by 2032, Driven …
According to the latest market analysis, the global general surgery devices market is set for robust growth, increasing from USD 21,786.29 million in 2024 to USD 35,399.63 million by 2032, expanding at a CAGR of 6.34% during 2025-2032. This growth reflects a surge in surgical procedures, continuous technological advancements, and rising demand for minimally invasive and robotic-assisted surgical techniques across healthcare systems worldwide.
DelveInsight's General Surgery Devices Market Report 2032 provides…
More Releases for Cancer
Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging…
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose.
Increase in incidence of target diseases like cancer is key driving factor which is expected to boost…
2019-2027 Oncology Nutrition Market is driven by Major Cancer Type - Head and Ne …
The "Global Oncology Nutrition Market Analysis to 2027" is a specialized and in-depth study with a special focus on the global market trend analysis. The report aims to provide an overview of oncology nutrition market with detailed market segmentation by cancer type and geography. The global oncology nutrition market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the…
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business.
Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:…
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine.
These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch…
Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung …
Researchmoz added Most up-to-date research on "Tumor Ablation Global Market From 2014 - 2024: Segmented Into Liver Cancer, Lung Cancer, Kidney Cancer, Bone Cancer, Breast Cancer, Prostate Cancer, And Others" to its huge collection of research reports.
Tumor ablation is the removal of the tumor cells or tissue with minimally invasive procedure. Tumor ablation devices are consists of an applicator (catheter), which is introduced into the tumor under imaging guidance. For…
